Flandre Ph, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Pialoux G, Aboulker JP, Brun-Vézinet F. Final analysis of the Trilège induction-maintenance trial: results at 18 months. AIDS 2002, 16 : 561-568. Lien PubMed
Paediatric European Network for Treatment of AIDS (PENTA). Comparison
of dual nucleoside-analogue reverse-transcriptase inhitor regimens with
and without nelfinavir in children with HIV-1 who have not previously
been treated: the PENTA 5 randomised trial. The Lancet 2002, 359 : 733-740.Lien PubMed
Flandre P, Durier C, Descamps D, Launay O, Joly V. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: Statistical analysis and potential biases. J Acquir Immune Defic Syndr 2002, 30 : 59-64.Lien PubMe
Flandre P, Peytavin G, Meiffrédy V, Saidi Y, Descamps D, Delagnes M, Brun-Vezinet F, Raffi R. Adherence
to antiretroviral therapy and outcomes in HIV-infected patients
enrolled in an induction/maintenance randomized trial. Antiviral Therapy 2002, 7 : 113-121. Lien PubMed
Joly V, Flandre P,
Meiffrédy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D,
Ruffault A, Certain A, Aboulker JP, Yeni P for the Novavir Study Group. Efficacy
of zidovudine compared to stavudine, both in combination with
lamivudine and indinavir, in human immunodeficiency virus-infected
nucleoside-experienced patients with no prior exposure to lamivudine,
stavudine, or protease inhibitors (Novavir Trial). Antimicrob Agents Chemother 2002, 46 : 1906-1913. Lien PubMed
Launay O, Gérard L,
Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G,
Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Patrick Yéni P. Nevirapine
or lamivudine plus stavudine and indinavir: examples of 2-class versus
3-class regimens for the treatment of human immunodeficiency virus type
1. Clin Infect Dis 2002, 35 : 1096-1105. Lien PubMed
Dorenbaum A, Cunningham
CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML,
Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL, for
the International PACTG 316 Team. Two-dose
intrapartum/newborn nevirapine and standard antiretroviral therapy to
reduce perinatal HIV transmission. A randomised trial. JAMA 2002, 288 : 189-198.Lien PubMed
Descamps D, Flandre P,
Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M,
Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F on behalf of the NOVAVIR
(ANRS 073) Study Group. Effect of zidovudine
resistance mutations on virologic response to treatment with zidovudine
or stavudine, each in combination with lamivudine and indinavir. JAIDS 2002, 31 : 464-471. Lien PubMed
Cunningham CK, Chaix ML,
Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy
JF, Bazin B, Mofenson L and Sullivan JL for the Pediatric AIDS Clinical
Trials Group Protocol 316 Team. Development
of resistance mutations in women on standard antiretroviral therapy who
received intrapartum nevirapine to prevent perinatal HIV-1 transmission:
a substudy of Pediatric AIDS Clinical Trials Group protocol 316. JFNDIS 2002;186:181-188. Lien PubMed
Saman M, Kruy LS, Glaziou P, Rekacewicz C, Leng C, Delfraissy JF. Feasibility
of antenatal and late HIV testing in pregnant women, in Phnom Penh
Cambodia: preliminary results of the PERIKAM/ANRS1205 study. AIDS 2002;16:950-951. Lien PubMed
Joly V, Flandre P, Meiffrédy V, Leturque N, Harel M, Aboulker JP, Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.Lien PubMed